注射用己酮可可碱联合奥扎格雷钠治疗急性脑梗死的临床研究

目的 分析注射用己酮可可碱联合奥扎格雷钠治疗急性脑梗死的临床疗效。方法 选取2015年3月—2020年10月北京市丰台中西医结合医院收治的112例急性脑梗死患者，按随机数字表法将患者分为对照组和治疗组，每组各56例。对照组静脉滴注注射用奥扎格雷钠，80 mg/次，溶于500 mL生理盐水中，2次/d。治疗组在对照组治疗基础上静脉滴注注射用己酮可可碱，0.2 g/次，溶于250 mL生理盐水中，1次/d，输注过程中患者平卧，2～3 h内滴注完成。两组疗程均为14 d。观察两组的临床疗效，比较两组治疗前后美国国立卫生研究院卒中量表（NIHSS）评分、简式Fugl-Meyer评定量表（FMA）评分、脑卒中专门化生存质量量表（SS-QOL）评分及血小板压积（PCT）、血小板聚集率（PAgT）、纤维蛋白原（FIB）和炎症相关指标[中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）]的变化。结果 治疗后，治疗组总有效率是94.64%，显著高于对照组的82.14%（P＜0.05）。治疗3、7、14 d后，两组NIHSS评分均较同组治疗前显著降低（P＜0.05）；治疗后，治疗组患者NIHSS评分显著低于对照组（P＜0.05）。治疗后，两组FMA、SS-QOL评分均较治疗前显著增加（P＜0.05）；治疗后，治疗组FMA、SS-QOL评分高于对照组（P＜0.05）。治疗后，两组PCT、PAgT、FIB、NLR、PLR均显著下降（P＜0.05）；治疗后，治疗组凝血及炎症相关指标显著低于对照组（P＜0.05）。结论 注射用己酮可可碱联合奥扎格雷钠治疗急性脑梗死的效果确切，能在较佳的安全性基础上，有效促进患者神经功能、运动功能恢复，改善凝血功能紊乱和机体炎症损害，利于患者生存状态提升。

Clinical study of pentoxifylline combined with ozagrel sodium in treatment of acute cerebral infarction

Objective To analyze the clinical efficacy of Ozagrel Sodium for injection combined with pentoxifylline in treatment of acute cerebral infarction. Methods A total of 112 patients with acute cerebral infarction admitted to Beijing Fengtai Hospital of Integrated Chinese and Western Medicine from March 2015 to October 2020 were selected and divided into control group and treatment group according to random number table method, with 56 cases in each group. Patients in the control group were iv administered with Ozagrel Sodium for injection, 80 mg/time, dissolved in 500 mL normal saline, twice daily. Patients in the treatment group were iv administered with Pentoxifylline for injection on the basis of the control group, 0.2 g/time, dissolved in 250 mL normal saline, once daily, the patient was supine during the infusion, and the infusion was completed within 2 to 3 h. The treatment course of both groups was 14 d. The clinical efficacy of the two groups was observed. After treatment, NIHSS score, FMA score, SS-QOL score, PCT, PAgT, FIB, NLR, and PLR in two groups before and after treatment were compared. Results After treatment, the total effective rate of the treatment group was 94.64%, which was significantly higher than that of the control group (82.14%, P < 0.05). After 3, 7 and 14 days of treatment, NIHSS scores in 2 groups were significantly lower than before treatment (P < 0.05). After treatment, the NIHSS score in the treatment group was significantly lower than that in the control group (P < 0.05). After treatment, FMA and SS-QOL scores in both groups were significantly increased compared with those before treatment (P < 0.05). After treatment, FMA and SS-QOL scores in the treatment group were higher than those in the control group (P < 0.05). After treatment, PCT, PAgT, FIB, NLR, and PLR in two groups were significantly decreased (P < 0.05). After treatment, coagulation and inflammation related indexes in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Ozagrel Sodium for injection combined with pentoxifylline has a definite effect in treatment of acute cerebral infarction, and can effectively promote the recovery of nerve function and motor function of patients, improve coagulation dysfunction and inflammation damage of the body, and improve the survival state of patients on the basis of better safety.